Critical Pharmaceuticals Limited
Critical Pharmaceuticals Limited is a biotechnology company with proprietary drug delivery technologies for injectagle sustained release and nasal delivery of challenging drugs includin proteins and peptides. Critical Pharmaceuticals are experts in drug delivery and are developing a number of ground breaking products to treat diseases as diverse as growth hormone deficiency and schizophrenia. Critical Pharmaceuticals' lead product is CP024, a nasal formulation of human growth hormone (hGH), that uses its CriticalSorb technology and is in Phase 1 clinical development. CP016 is Critical Pharmaceuticals' long acting growth hormone product that has completed pre-cliniical development. Critical Pharmaceuticals actively partners its drug delivery technologies and candidate drugs with pharmaceutical and biotechnology companies.
When we backed the company at start up, we recognised the simplicity of the technology and its potential for improving the delivery of existing molecules and, therefore, for improvements in the patient experience.
Our investment has supported the formulation work, pre-clinical and clinical development of the Company's products.